A Multicenter, Double-blind, Active-controlled, Randomized, Parallel Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients
Latest Information Update: 25 Oct 2024
At a glance
- Drugs DA-2803 (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Dong-A ST
- 23 Oct 2024 Status changed from recruiting to completed.
- 26 Jul 2023 New trial record